16+
Major trials tracked
GLP-1 & incretin therapies · Live ClinicalTrials.gov data
Orforglipron clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 orforglipron trials on ClinicalTrials.gov by enrolment, 4 of them actively recruiting. The next phase 3 primary completion among them is expected Nov 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
16
Phase 3 trials
4
Actively recruiting
Nov 2026
Next phase 3 primary completion
25,373
Participants across trials
Eli Lilly and Company
Lead sponsor by trial count
orforglipron (16)10 active2023–2033
orforglipron
'23
'24
'25
'26
'27
'28
'29
'30
'31
'32
'33
orforglipron
ACHIEVE-4P3
ATTAIN-1P3
ATTAIN-2P3
ACHIEVE-1P3
ACHIEVE-3P3
ACHIEVE-5P3
ACHIEVE-2P3
ATTAIN-OSAP3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)P3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesP3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityP3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesP3
ATTAIN-OA PAINP3
RESTRAIN-SUIP3
ATTAIN-PADP3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)P3
Upcoming readouts
9 ahead · orforglipron
Select a trial to load its full ClinicalTrials.gov record.
Key orforglipron trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07202884 | RESTRAIN-SUI — A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight | Phase 3 | Recruiting | Mar 2028 |
| NCT07153471 | ATTAIN-OA PAIN — A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the … | Phase 3 | Recruiting | Apr 2028 |
| NCT07223593 | ATTAIN-PAD — Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Phase 3 | Recruiting | Jun 2028 |
| NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular D… | Phase 3 | Recruiting | Aug 2031 |
| NCT05869903 | ATTAIN-1 — A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comor… | Phase 3 | Active, not recruiting | Jul 2025 |
| NCT06649045 | ATTAIN-OSA — A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | Phase 3 | Active, not recruiting | Nov 2026 |
| NCT06993792 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Typ… | Phase 3 | Active, not recruiting | Aug 2027 |
| NCT06972472 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Active, not recruiting | Aug 2027 |
| NCT06972459 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related… | Phase 3 | Active, not recruiting | Aug 2027 |
| NCT06948422 | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (A… | Phase 3 | Active, not recruiting | Sept 2027 |
| NCT05971940 | ACHIEVE-1 — A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control… | Phase 3 | Completed | Apr 2025 |
| NCT05872620 | ATTAIN-2 — A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Completed | Aug 2025 |
Related drug pipelines
FAQ
- How many clinical trials are running for orforglipron?
- ClinicalTrials.gov lists more than 16 phase 2–4 orforglipron trials. This page tracks the 16 largest by enrolment: 0 phase 2, 16 phase 3, and 0 phase 4 among them, with 4 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare orforglipron against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.